TPM3 and cancer: Selirectinib, repotrectinib, and taletrectinib are among the investigational drugs currently under clinical evaluation as effective TRK inhibitors to counter resistance to first-generation NTRK inhibitors in cancer (Supplementary Table S1) [161].